MedTrace Logo

A Study of GSK256073 in Subjects With Type 2 Diabetes Mellitus Who Are Being Treated With Metformin

NCT01376323 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 92

Last updated 2017-10-11

Study results available
· View outcomes & findings →

Summary

The aim of this combined, two part study is to evaluate the safety and glucose lowering effects of GSK256073 when administered to diabetic subjects for 12 weeks.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

GSK256073 1mg

GSK256073 1mg capsule

DRUG

GSK256073 5mg

GSK256073 5mg capsule

DRUG

GSK256073 10mg

GSK256073 10mg capsule

DRUG

GSK256073 25mg

GSK256073 25mg capsule

DRUG

Placebo

placebo capsule

DRUG

Sitagliptin 100mg

Sitagliptin 100mg capsule

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-07-13
Primary Completion
2012-09-16
Completion
2012-09-17

Countries

  • United States
  • France
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01376323 on ClinicalTrials.gov